secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001193125-22-311027
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO RA Session II resigns; Chairman Sean Nolan appointed CEO; Sukumar Nagendran named President and Head of R&D
--------------------------------------------------------------------------------

- RA Session II resigned as President and CEO effective Dec 16, 2022; remains on Board.
- Sean Nolan (Chairman) appointed CEO immediately; compensation not yet finalized.
- Sukumar Nagendran, M.D., appointed President and Head of R&D; Suyash Prasad becomes Chief Medical Officer.
- Company will file separation terms later; compensation for Nolan and Nagendran to be amended.
- Company to host investor call mid-January after FDA Type B meeting on GAN program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/d398679d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer